GlassScriptPhysician profile
Emmalyn A Bady-Mcdowell
NPI 1336134584
$5,153.47
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2020: $166 · 2021: $762 · 2022: $1,074 · 2023: $1,156 · 2024: $1,810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,965.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $805.38 | 2021-2024 | Spravato, Invega Sustenna |
| Abbvie INC. | $596.30 | 2021-2024 | Vraylar |
| Supernus Pharmaceuticals, INC. | $550.05 | 2024 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $434.63 | 2019-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Corium, LLC | $348.26 | 2021-2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $309.16 | 2019-2024 | Trintellix |
| Ironshore Pharmaceuticals INC. | $293.27 | 2020-2024 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $252.50 | 2021-2024 | Caplyta |
| Almatica Pharma LLC | $209.46 | 2022-2024 | Loreev Xr, Sertraline Hcl |
| Eisai INC. | $185.95 | 2020-2022 | |
| Alkermes, INC. | $185.37 | 2021-2024 | Aristada, Lybalvi |
| Tris Pharma INC | $182.68 | 2023-2024 | Dyanavel Xr |
| Neurocrine Biosciences, INC. | $114.63 | 2019-2022 | |
| Axsome Therapeutics, INC. | $89.86 | 2022-2023 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $83.80 | 2024 | Fanapt |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $82.59 | 2021-2023 | Belsomra |
| Sunovion Pharmaceuticals INC. | $80.73 | 2020-2022 | |
| Allergan, INC. | $78.32 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $75.28 | 2023-2024 | Austedo Xr, Uzedy |
| Neos Therapeutics, LP | $61.35 | 2019-2021 | |
| Lundbeck LLC | $37.84 | 2020-2023 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $28.10 | 2024 | |
| Idorsia Pharmaceuticals US INC | $21.80 | 2022 | |
| Sage Therapeutics, LLC | $18.67 | 2024 | |
| Acadia Pharmaceuticals INC | $16.54 | 2024 | Nuplazid |
| Shire North American Group INC | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emmalyn Bady-Mcdowell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.